A high rate of intratumoral heterogeneity is also common for ALK rearrangements in lung cancer [39], PTEN deletion in prostate cancer [40], as well as BRAF mutation in pulmonary adenocarcinoma [41]. This evidence concerns the gene ALK and prostate carcinoma.